The role of bevacizumab in targeted vascular endothelial growth factor therapy for epithelial ovarian cancer: an updated systematic review and meta-analysis.

Onco Targets Ther · 2018 · PMC5788992 · PMID 29416352

Europe PMC DOI

hedged sentence

0.0600

closest p · 1.2× alpha

0.0600

boldest claim

The sentences

showed a trendP =0.06so close (0.05 < p ≤ 0.1)

The subgroup that received a combination of bevacizumab with a regimen of chemotherapy showed a trend of improvement without significance (HR =0.91; 95% CI, 0.83–1.00; Z=1.91, P =0.06 for PC-based chemotherapy, HR =0.91; 95% CI, 0.77–1.07; Z=1.16, P =0.25 for non-PC-based chemotherapy).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.